Peter Angus

Houlihan Lokey Capital, Inc. is a registered broker/dealer headquartered in Los Angeles, California. The firm was founded in 1996 and they are a subsidiary of Houlihan Lokey, Inc. (NYSE: HLI). Houlihan Lokey Capital provides an array of trading and execution services for their clients. They also have the ability to serve as underwriter or bookrunner with respect to traditional debt and equity offerings, including leveraged loans and public offerings of debt, equity-linked, and equity securities.

UCMS Group Ltd. provides customer management and business process outsourcing services for telecommunications, finance, energy, transport and public sectors. It also provides services to electricity retailers, infrastructure operators and technology resellers. The company was founded in 1995 and is headquartered in South Melbourne, Australia.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO.

The American Society for Clinical Pharmacology & Therapeutics is a scientific and professional organization that serves the disciplines of clinical pharmacology and translational medicine. The non-profit company is based in Alexandria, VA. The CEO of the company is Sharon Swan.

The International Society for Pharmaceutical Engineering is a nonprofit association that focuses on scientific, technical, and regulatory advancement throughout the entire pharmaceutical lifecycle. The non-profit company is based in Tampa, FL. The company engages with all levels of regulators to ensure that their education, training, document development, and interpretation are cutting-edge and focused on enabling the production and supply of therapies and devices with unmatched levels of flow, efficiency, and quality sustainably and at scale. John Bournas has been the CEO of the company since 2015.